We sought to identify susceptibility genes for high-grade serous ovarian cancer (HGSOC) by performing a transcriptome-wide association study of gene expression and splice junction usage in HGSOC-relevant tissue types (N = 2,169) and the largest genome-wide association study available for HGSOC (N = 13,037 cases and 40,941 controls). We identified 25 transcriptomewide association study significant genes, 7 at the junction level only, including LRRC46 at 19q21.32, (P = 1 × 10
I
nvasive epithelial ovarian cancer (EOC) is a heterogeneous disease with a major heritable component 1 . There are several histological subtypes of invasive EOC, each associated with different genetic and epidemiological risk factors, clinical features and likely cells of origin. High-grade serous ovarian cancer (HGSOC) is the most common histotype, representing about two-thirds of cases. Highly penetrant germline mutations in the homology-directed repair genes including BRCA1 and BRCA2 are the most significant genetic risk factors for HGSOC, but only account for about 10% of cases 1 . A major fraction of the remaining EOC risk is due to common, low-penetrance risk alleles; over the last few years, genome-wide association studies (GWAS) have identified 39 different regions of the genome associated with EOC risk, mainly in European populations [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Typically, SNPs associated with disease risk are in the non-protein-coding genome, which suggests they function by altering the activity of non-coding biofeatures (for example, DNA enhancers, non-coding RNAs) that regulate gene expression. Expression quantitative trait locus (eQTL) analysis can be used to identify associations between risk genotypes and gene expression; several studies have successfully used this approach to identify putative susceptibility genes at GWAS risk loci 2, 3, 14, 15 , including in EOC 2, 3, [6] [7] [8] [9] 14, 15 . Recently, transcriptome-wide association studies (TWAS) have been proposed as a principled approach to integrate eQTL analyses with GWAS to identify genes whose genetically regulated expression is associated with disease risk [16] [17] [18] [19] [20] . For a given gene, TWAS use eQTL data to 'impute' the total expression across a large cohort of genotyped individuals, followed by a test of association with disease risk. TWAS may additionally increase power versus single SNP association testing, either by reducing the multiple testing burden or aggregating multiple expression-altering variants into a single test. However, TWAS may also identify significant associations due to pleiotropy between expression-and risk-altering variants or the variants they tag 16, 21 . Therefore, a TWAS is a first step to prioritize putative target genes, with experimental validation needed to establish causality.
In the current study, we established the most comprehensive genome-wide genotype-gene expression datasets available, with >2,000 eQTL samples in primary HGSOC, EOC precursor tissues (ovarian and fallopian epithelial cells) and other hormonal-related cancers (breast and prostate cancer), to perform multi-tissue TWAS in the largest ovarian cancer GWAS available (N > 50,000). In addition to performing traditional TWAS that test for association at total abundance levels, we extend the TWAS methodology to integrate splicing quantitative trait loci (QTLs) by also testing exon junction levels for association to EOC (splice-transcriptome-wide association study (spTWAS)). We identify 25 genes whose expression is significantly associated with EOC risk at genome-wide significance, 7 of which are only significant in the spTWAS, thus underscoring the utility of incorporating splicing association analyses. We use in vitro assays to validate the functional significance of splicing QTL associations for CHMP4C and evaluate a gene knockout screen in HGSOC 22 to establish the functional essentiality for three of the new spTWAS genes we identified: HAUS6, KANSL1 and PRC1.
results
Genetic control of gene expression after tumorigenesis. First, we investigated the genetic control of gene expression in EOC precursor tissues and HGSOC. We assayed genotype and gene expression, and quantified splicing data for 115 primary normal ovarian surface epithelial cells (OSECs), 70 primary normal fallopian tube secretory epithelial cells (FTSECs) and 394 primary HGSOCs profiled by The Cancer Genome Atlas (TCGA). FTSECs are probably precursor cells for the majority of HGSOCs [23] [24] [25] [26] [27] while OSECs are also a postulated cellular origin for the disease [28] [29] [30] [31] [32] [33] . We quantified the SNP-heritability (h 2 g ) and genetic correlation (r g ) of gene expression and splicing between pairs of tissues (see Methods). For a given tissue, cis-h 2 g is defined as the fraction of phenotypic variance explained by SNPs within 500 kb of the gene boundary. For a pair of tissues, cis-r g is defined as the correlation of causal genetic effects on expression across all SNPs within 500 kb of the gene boundary. The average cis-h 2 g was significant in all tissues, with an average of 0.026 for overall expression and 0.021 for splice variation, like previous observations across different tissues (Supplementary Table 1 ). There was a higher mean cis-r g between FTSECs and HGSOCs (r g = 0.071, s.e.m. = 0.031; Table 1 ) than between OSECs and HGSOCs (r g = −0.022, s.e.m. = 0.029) consistent with the hypothesis that FTSECs are the more likely precursor cell type for HGSOC. We observed a similar, albeit non-significant, trend for heritable splicing events, with a genetic correlation of 0.024 (s.e.m. = 0.016) between HGSOCs and FTSECs, and −0.018 (s.e.m. = 0.013) between OSECs and HGSOCs. There was a greater genetic correlation for both overall gene expression and splicing events between OSECs and FTSECs (r g = 0.359, s.e.m. = 0.046 for overall expression; r g = 0.302, s.e.m. = 0.023 for splicing) indicating that genetic control of gene expression is altered during tumorigenesis. Lastly, we evaluated r g between four molecular subtypes of HGSOCs characterized by gene expression signatures by TCGA 34 but observed no significant divergence from 1.0 and few individually significant genes (Supplementary Tables 2 and 3 ). Therefore, we treated all HGSOCs as a single group for subsequent analyses.
Cross-cohort validation of the TWAS models. We investigated the utility of the expression data assayed in OSECs, FTSECs and HGSOC and other hormonally regulated cancers (breast and prostate) in building prediction models for TWAS (Fig. 1) . In addition to OSEC, FTSEC and HGSOC data, we included RNA sequencing (RNA-seq) data from 1,027 primary breast tumors, 84 matched normal precursor tissues and 483 primary prostate cancers from TCGA 2, 9, 35 . For the TCGA cohorts, we also used exon junction events as a measure of alternative splicing to identify predictors that may not be observed through total expression (see Methods). We defined a 'panel' as a tissue-state-phenotype triplet (for example, prostate-tumor-splicing) and performed normalization, correction and model building within each panel separately so as not to induce confounding due to cross-panel differences. A strength of the TWAS approach is that it is immune to the reverse-causal effects of disease on gene expression (independent of genetics). We show both theoretically and by simulation that this holds for case-only study design (Supplementary Note and Supplementary  Fig. 1 ). Each panel underwent stringent quality control and included as covariates genetic and gene expression/splicing principal components, local somatic structural variation and relevant clinical factors (Supplementary Note and Supplementary Table 4) . Accounting for local structural variants significantly increased gene expression heritability for ovarian and breast tumors ( Supplementary Fig. 2 ), but tumor and/or pathological features such as purity, grade and/ or stage and hormone receptor status did not show substantial genetic heterogeneity except in the case of ovarian tumor expression from BRCA1/2 somatic mutation carriers (Supplementary Note, Supplementary Fig. 2 and Supplementary Tables 3 and 5). A total of 13,762 significantly heritable genes and 53,579 significantly cis-heritable exon junction events were identified across all cohorts (cis-h 2 g P < 0.01; for detailed evaluation of cis-locus and heritability parameters see Supplementary Note, Supplementary Table 6 and Supplementary Figs. 3 and 4) . We then trained multiple penalized predictive models using all SNPs in a locus and evaluated predictive accuracy by fivefold cross-validation against the actual measured expression (see Methods). The mean crossvalidated predictor R 2 was 0.066 (s.e.m. = 4 × 10 −4 ) and highly significant (median predictor cross-validation P = 4.6 × 10 −4 ), consistent with previous findings that low average heritability of gene expression can be compensated for by sample size sufficient to produce reliable genetic predictors (Supplementary Table 7) . Next, we leveraged the multiple independent cohorts analyzed in the study to assess the replication rates for our predictive models with out-of-sample gene expression (Supplementary Note and  Supplementary Tables 8 and 9 ). Both out-of-sample correlation and model significance were high across all cohorts and comparable to previous multi-tissue studies 36 . Interestingly, predictive models built in tumors had the highest out-of-sample accuracy in the breast and prostate normal panels, consistent with tumor expression capturing genetic effects that are present in normal tissues. Predicting into the normal FTSEC and OSEC samples generally yielded the lowest replication (Supplementary Tables 8 and 9) , probably due to the small size and heterogeneity of these cohorts. (Notably, predictors constructed in the normal FTSEC and OSEC samples still achieved high out-of-sample accuracy.) Similar trends were observed when predicting into healthy samples from the Genotype Tissue Expression (GTEx) cohort (Supplementary Note  and Supplementary Tables 10 and 11 ; see Supplementary Fig. 5 for complete details of our validation procedure).
TWAS for EOC identifies candidate susceptibility genes. We performed TWAS using the GWAS data from 13,037 HGSOC cases and 40,941 controls estimated by the Ovarian Cancer Association Consortium 7 and our trained gene expression/splicing models (Fig. 1) . The genetically predicted expression of 32 gene-level models (18 unique genes) and 74 junction-level models (17 unique genes) were significantly associated with risk after Bonferroni correction for 66,764 total tests ( Supplementary Fig. 6 ). TWAS may identify coincidental genetic associations due to partial tagging between the expression and disease-causing variants; thus, we performed additional conditioning and colocalization analyses on a locus-by-locus basis (see Methods). We validated the expression models for each of the significant TWAS associations by predicting into the independent cohorts from other tissues and/or states (Supplementary Tables 12-14) ; 82 out of 106 associated models were significantly correlated with expression and/or splicing measured in at least one independent cohort (after Bonferroni correction for 388 model-by-cohort pairs tested, with 92 out of 106 nominally significant after Bonferroni correction for 4 cohorts tested). Mean replication R 2 was 0.11 for overall expression and 0.10 for splicing; we observed no significant differences between the target datasets. Sixteen out of 32 gene-level models were significantly correlated with gene expression (after Bonferroni correction) in the matching tissue in healthy GTEx samples and mean replication R 2 was 0.12, demonstrating little average loss in predictive accuracy in healthy independent samples relative to independent TCGA samples (Supplementary Table 15 ). Overall, we found that more heritable and better cross-validating genes were more likely to show up as significant TWAS associations (Supplementary Note, Supplementary Table 16 and Supplementary Figs. 7-11 ).
New genes implicated through TWAS. We first characterized genelevel events across the six tissue types, identifying 32 TWAS associations for 18 unique genes after Bonferroni correction ( Table 2,  Supplementary Table 17 and Supplementary Fig. 6 ). A single association was detected in FTSECs-the non-coding RNA TIPARP-AS1 at chromosome 3q25.31 (TWAS P = 2.2 × 10
−25
). Seven genes were associated with risk in HGSOC; CHMP4C 6 at chromosome 8q21.13 and six genes located within an inversion at chromosome 17q21.31 (ref. 37 ). ARL17A was a notable example where ovarian-specific eQTLs explained the local GWAS signal; however, significant eQTLs observed in breast and prostate cancer were independent (Fig. 2 , Supplementary Figs. 12 and 13 and Supplementary Table 18 ). After conditioning on the ARL17A ovarian tumor model (see Methods), the most significant conditional GWAS association in this locus was P = 0.002, whereas after conditioning on the ARL17A breast tumor model, the most significant conditional GWAS association was
, further supporting this as an ovarian cancer-specific association. ARL17A has not been previously implicated in ovarian cancer, although KANSL1-ARL17A gene fusions have been implicated in pancreatic cancer 38 . Additionally, RCCD1 at chromosome 15q26, which had previously been implicated in a meta-analysis of breast and ovarian cancer 9 , was transcriptome-wide significant (TWAS P = 1.5 × 10 −7 in prostate tumors) in the current study. A follow-up colocalization analysis showed that 21 out of 32 TWAS associations exhibited strong evidence of a single shared causal variant (posterior probability 4 (PP4) > 0.8) and only 4 out of 32 had evidence of joint causal variants (PP3 > 0.2). The number of significant associations was strongly correlated with the number of tested genes (R 2 = 0.86) suggesting that these findings are driven by the size and quality of the expression reference dataset, rather than tissue specificity (Supplementary Fig. 14) .
We replicated 10 of 18 unique genes using independent prediction models from the GTEx study after Bonferroni correction (Supplementary Table 19 ). Only two were significant using the GTEx ovary models-the paralogs LRRC37A and LRRC37A2-which were significant in nearly all tissues except for testicular and normal prostate tissues (Supplementary Table 15 ). A TWAS analysis of all 84,064 available GTEx models identified two additional transcriptome-wide significant loci: MLLT10 at chromosome 10p12.31, which was significant in the leg and spleen; and DNALI1 at chromosome 1p34, which was significant in nine tissues (but not in breast, prostate or ovary tissues). The DNALI1 locus was previously reported as genome-wide significant in serous EOC where the RSPO1 gene was proposed as a putative target gene, but no eQTL association was detected 11 . Conditioning on the predicted expression of DNALI1 accounted for all the genome-wide significant signal, consistent with these genes being potential mediators of the association ( Supplementary Fig. 15 ). In breast tissue, where models were trained in TCGA tumor and normal tissues and GTEx healthy tissues, genes that were predictable in multiple cohorts produced highly concordant TWAS test statistics, underscoring the consistency of these models between tumor/normal and case/control expression ( Supplementary Fig. 5 ).
New transcripts implicated through junction spTWAS. Next, we performed a spTWAS across all significantly heritable exon junction events, identifying 74 spTWAS associations with EOC risk in 18 unique genes (after Bonferroni correction; Table 2 and  Supplementary Table 20) . This included seven genes that did not have a significant gene-level TWAS association in the TWAS analysis of overall expression. Colocalization analysis 39 showed that 58 out of 74 associations were consistent with a shared causal variant (posterior on shared >0.8) and 70 out of 74 were inconsistent with a single distinct causal variant (posterior on distinct <0.2). Three loci contained only a single significantly associated gene; we investigated these loci in detail.
First, we identified a spTWAS association for PRC1 (in breast tumors) that fully explains the GWAS signal at the 15q26.1 locus (TWAS P = 8.9 × 10 −8 , PP4 = 1.0), which is associated with both breast and ovarian cancer risk 9 ( Fig. 3 ). This spTWAS model replicated significantly in ovarian tumor tissue (P = 8.6 × 10 −4 ; Supplementary Table 13) . Notably, we found no significant eQTLs for overall expression of PRC1, highlighting a genetic effect on splicing that is independent of total expression. We separately identified a significant TWAS association for the nearby RCCD1 gene in prostate tumors, which is modestly correlated with PRC1 ( Supplementary  Fig. 9 ) and was previously implicated as a candidate breast/ovarian cancer susceptibility gene 9 . Second, we identified multiple spTWAS associations for CHMP4C (in all tumor panels), which fully explained the 8q21 locus. CHMP4C harbors a missense risk variant and was previously implicated by eQTL analysis 6 . In the current study, the lead splice quantitative trait locus (spQTL; rs74758321;
) is within 300 base pair (bp) of the splice junction and in perfect linkage disequilibrium with the top GWAS SNP at this locus, further implicating splicing as the potential causal mechanism (see also CHMP4C functional validation below). Third, we identified a spTWAS association for HAUS6 (in prostate tumors) at the 9p22.1 locus (TWAS P = 2.8 × 10
, PP4 = 0.7, PP3 = 0.01), which was not genome-wide significant (GWAS P = 5.9 × 10
−6
). Although a conditional analysis fully accounted for the local GWAS signal ( Supplementary Fig. 16 ), the cross-validation accuracy of the predictive model was nominally significant (P = 2.8 × 10
) and the model did not replicate in other tissues (Supplementary Table 13 ), necessitating further replication to confirm this locus.
Most associations (51 out of 74) were at the 17q21.31 locus within an inversion polymorphism spanning approximately 900 kb. This region contains hundreds of variants in high linkage disequilibrium, all representing putative causal alleles and involved in genetic co-regulation of nine genes, with evidence of multiple clusters of independent associations (Supplementary Fig. 11 ). We observed a complex co-regulation of more than three unique genes at one other locus-19p13.11-with evidence of multiple independent associations. We performed stepwise conditional analysis of all significant TWAS/spTWAS associations in the locus to identify the minimal set of genes that jointly explained the most genome-wide significant signal. The final model contained two splicing events for the BABAM1 gene (chr19:17378336-17379565 in ovarian tumors and chr19:17378336-17379603 in prostate tumors, correlated with R 2 = 0.59), reducing the lead GWAS SNP from P = 7.8 × 10 Supplementary Figs. 11 and 17 ). The 19p13.11 risk locus is also associated with triple-negative breast cancer 2 and BABAM1, a known BRCA1-interacting protein, is therefore a compelling target gene. Our previous gene-level functional studies failed to find strong functional evidence of a role for BABAM1 in ovarian and breast tumorigenesis, but instead implicated the neighboring genes ABHD8 and ANKLE1 (ref.
2
). These new analyses suggest that characterizing the functional significance of BABAM1 splice variants is warranted. Further studies are needed to understand these apparently contradictory results that suggest either multiple causal variants or complex local haplotype structure.
GWAS variance and pleiotropy explained by TWAS associations.
Overall, the GWAS contained 13 contiguous genome-wide significant regions, of which 6 were within 500 kb of a TWAS or spTWAS association (Supplementary Table 21 ). These 6 regions implicated a total of 106 associated features out of 1,134 tested, demonstrating a substantial number of heritable gene-tissue combinations that have also been ruled out as likely cis-targets. All gene expression and splicing models, without thresholding, explained 31% (s.e.m. = 11%; P = 3.5 × 10 −3 ) of EOC SNP heritability (estimated by a modified linkage disequilibrium score regression; see Methods). This estimate includes any tagged genetic effects that alter expression and risk independently; thus, it should be interpreted as an upper bound.
We further tested the 106 transcriptome-wide significant features (74 splice events and 32 genes) for pleiotropic associations with breast cancer risk from a recent breast cancer risk GWAS 40 . Seventy out of 106 features showed evidence of significant TWAS association (P < 0.05 for the 106 features), demonstrating extensive pleiotropy between breast and ovarian cancer at these loci that appears to operate through the same genes (Supplementary Table 22 ). No significant differences were observed in the rate of pleiotropic association using breast, prostate or ovarian models (Supplementary Table 23 ). Of the 70 pleiotropic associations, 4 were genome-wide significant (P < 5 × 10
) for breast cancer: gene-level association with RCCD1 and exon-level associations with PRC1, LRRC37A and KANSL1. These results highlight two robust genome-wide significant loci associated with breast and ovarian cancer that also exhibit effects on the expression of the same genes. We repeated the same analysis for a recent GWAS for prostate cancer 41 but did not identify any features significant after Bonferroni correction, suggesting that the extensive expression-based pleiotropy we observed between breast and ovarian cancer is not expected by chance.
Functional assays support the CHMP4C splicing association.
As described earlier, we identified four spTWAS associations in the CHMP4C gene, the most significant of which was rs74758321, which is in perfect linkage disequilibrium with the top GWAS risk SNPs for ovarian cancer identified in this region. In silico and in vitro functional analyses were performed to establish if this is a likely causal SNP at this locus. SNP rs74758321 is most significantly associated with the chr8:82665476:82667605 junction in ovarian, breast and prostate tumors, with similar effect sizes across all phenotypes (Supplementary Table 24 ). In a joint regression testing of the association between the SNP and all four splice junctions, this junction was the most significant feature in all tumor cohorts; however, it was not significant in normal tissues, although a significant joint association was observed for other junctions also (Supplementary Table 25 ). This was also the only variant identified that fell within the consensus splice site sequence (within 300 bp of a junction). Therefore, we evaluated the effects of different alleles of rs74758321 on splicing in an in vitro splicing reporter assay performed in FUOV1 ovarian cancer cells. We observed exon inclusion (7.6 ± 1.6%) more frequently in cells transfected with the ' A' allele compared to the 'G' allele (P = 0.0024, two-tailed, paired Student's t-test) (Fig. 4) . Importantly, we did not observe functional evidence supporting transcriptional regulatory activity or the previously implicated missense variant. Enhancer scanning assays performed to evaluate the allele-specific enhancer activity of approximately 2 kb genomic tiles containing nine credible (1:100) causal variants identified in GWAS, including rs74758321, at this locus failed to detect any differential regulatory activity (Supplementary Note and Supplementary Fig.   18 ). In addition, we performed a CHMP4C protein stability analysis to determine the effect of the missense variant SNP rs35094336 (p.Ala232Thr). No difference was observed in protein expression Genes show evidence of essentiality in a knockout screen. We explored the functional role of the 25 candidate susceptibility genes identified from our TWAS and spTWAS analyses using publicly available data from a gene essentiality screen 22 . We used gene knockout data for 24 genes in 13 HGSOC cell lines (Fig. 5) . Three genes showed evidence of essentiality (CERES score < −0.5): KANSL1 (mean CERES score = −0.53, s.d. = 0.15); HAUS6 (mean CERES score = −0.84, s.d. = 0.07); and PRC1 (mean CERES score = −1.13, s.d. = 0.14). PRC1 shows similar levels of essentiality as MYC, a key oncogenic transcription factor in many tumor types, including ovarian cancer 42 . All three genes were identified only through the spTWAS and not previously reported. Indeed, the mean CERES score across significant spTWAS genes (−0.21, s.e.m. = 0.03) was significantly lower (that is, more essential) than that of genes not associated through splicing (−0.01, s.e.m. = 0.02; P = 4.8 × 10
for the difference by Wilcoxon signed-rank test). This significant difference suggests that risk variants affecting splicing, and thus protein structure, may be more likely to target essential genes in ovarian cancer cells than risk variants that apparently only affect transcription (that is, protein abundance). Since the CERES functional screens model complete gene knockouts, further functional assays of specific isoforms and allelic series are required to validate this hypothesis.
Discussion
In this study, we integrated tissue-specific gene expression and genotyping data with the largest GWAS dataset available for HGSOC 7 to identify 25 candidate susceptibility genes, one of which was experimentally validated and three which showed promising functional evidence of essentiality. The spTWAS analysis identified seven genes that were not implicated by the gene-level TWAS, nearly doubling the number of candidate susceptibility genes we identified. This included PRC1 (at chromosome 15q26.1), which explained all the GWAS signal while exhibiting no eQTL association and was not previously identified in a locus-specific eQTL analysis. Notably, PRC1 showed similar levels of essentiality as MYC (a known essential gene and likely GWAS target gene in HGSOC 13 ) strongly indicating that PRC1 plays a functional role in the development of ovarian tumors. In breast, ovarian and prostate tumors we identified an spTWAS association for CHMP4C, at chromosome 8q21. 13 . In an in vitro splicing assay, the two alleles of rs74758321 were associated with significantly different rates of exon 3 inclusion. We performed comprehensive testing for allele-specific activity for all candidate causal variants in the region, using a set of in vitro assays that are commonly used to evaluate allele-specific activity of risk SNPs, including enhancer scanning, electrophoretic mobility shift assays and protein stability assays 2, 40, [43] [44] [45] . Beyond the validated role for rs74758321 in splicing, there was no evidence to support a functional role for any of the other candidate causal variants at this locus, indicating that rs74758321 is the most likely 'causal' variant at this risk locus. Taken together, these findings indicate that alternative splicing should be considered more broadly in post-GWAS functional analyses. CHMP4C expression has been implicated in several cancers and has been proposed as a diagnostic tumor marker and therapeutic target for ovarian cancer 46, 47 . We observed a striking overlap between significant TWAS genes in GWAS for HGSOC and a recent GWAS of breast cancer 40 , including genome-wide significant associations with PRC1 and KANSL1. These findings merit further studies based on TWAS methodologies to identify pleiotropy and common cancer susceptibility genes for these cancers.
It remains likely that our TWAS analysis missed an unquantifiable proportion of true associations, while some associations may represent false-positive findings due to chance co-regulation 21 . This is emphasized by a recent parallel publication from Lu et al. 48 reporting a TWAS for ovarian cancer using total expression models and HGSOCs (n = 394). ARL17B and TIPARP-AS1 were not evaluated in the CERES screen; therefore, they were excluded from the plots. The boxes in each plot represent the first and third quartiles; the whiskers extend to the 1.5× IQR.
constructed in the GTEx cohort. The use of distinct transcriptomic data in our study and our focus on splicing variation probably contribute to the differences in the candidate ovarian cancer susceptibility genes identified in each study. In particular, the one new locus identified by Lu et al.
48
, FZD4 at chromosome 11q14.2 and a plausible candidate because of its role as a member of the frizzled gene family associated with Wnt signaling, was not heritable in any of the tissues we investigated (h 2 g < 0.006 in any tissue). We note that selecting the appropriate tissue and/or cell type for TWAS is critical to avoid false-positives in causal gene identification from TWAS and remains an active research area for TWAS analyses; see Wainberg et al. 21 for a broader discussion of tissue choice in causal gene identification following TWAS or Phelan et al. 7 for a specific discussion of tissue of origin for the different histotypes of EOC. Future studies to improve the power of TWAS analysis in ovarian cancer will need to establish substantially larger gene expression and genotyped datasets for normal precursor tissues, HGSOC and other EOC histotypes that were not evaluated in the current study.
In summary, we have performed a TWAS based on the integration of GWAS data for HGSOC and gene expression data for both normal and tumor tissues associated with HGSOC pathogenesis, to identify candidate susceptibility genes associated with inherited HGSOC risk. Most importantly, this study established spT-WAS associations as a major component of HGSOC heritability, a principle that also probably applies to many other phenotypes.
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Methods
Data processing and quality control. Genotypes. Germline DNA from normal OSEC and FTSEC samples were genotyped using the OncoArray platform 7 . For the TCGA data, SNP genotype calls using Birdsuite (v.1.5.5) were downloaded from the TCGA legacy archive and imputed using the EAGLE pipeline provided by the Michigan Imputation Server. The following genotype quality control was performed across all studies. SNPs were retained if they had imputation INFO >0.9, locus missingness <5%, Hardy-Weinberg equilibrium two-tailed P > 5 × 10 −6 and minor allele frequency >1% (thresholds based on GTEx Consortium recommendations). Individuals were excluded if they had >5% missing sites. Two genotype principal components were computed to account for ancestry and included as covariates in all subsequent analyses.
Gene and exon expression in HGSOC precursor tissues. OSECs and FTSECs were collected from histologically normal ovaries and fallopian tubes removed from women diagnosed with ovarian, uterine or cervical cancer. Short-term cultures were established 49, 50 . OSECs were collected using a Cytobrush and cultured in NOSE-CM media containing 15% fetal bovine serum (FBS; HyClone, Fisher Scientific), 34 μg ml −1 bovine pituitary extract, 10 ng ml −1 epidermal growth factor (Thermo Fisher Scientific), 5 μg ml −1 insulin and 500 ng ml −1 hydrocortisone (Sigma-Aldrich). Fallopian epithelia were dissociated from stromal tissues using Pronase/DNase I digestion (Roche and Sigma-Aldrich, respectively) for 48-72 h at 4 °C. Purified epithelia were cultured on Collagen I (Sigma-Aldrich) using DMEM/F12 base media supplemented with 2% Ultroser G serum substitute (Pall Corporation). At approximately 80% confluency, cells were lysed using the QIAzol lysis reagent and RNA extracted using the RNeasy Mini Kit (both QIAGEN). RNA-seq was performed by the University of Southern California Epigenome Core Facility using 50 bp single-end reads. All data processing was performed using R, Bioconductor and packages therein.
RNA-seq data for 394 HGSOC samples were obtained from the TCGA data portal as protected data (raw sequencing, FASTQ files) and downloaded via the Cancer Genomics Hub's GeneTorrent (2016-08-01). Data were aligned to a reference genome (hg19) using STAR (v.2.5.1b). Quality control of aligned samples was performed using RSeQC (v.2.6.3). Guanine-cytosine bias and batch effect corrections were performed using EDASeq (v.2.12) and the sva package. To adjust for batch effects, we used an empirical Bayes framework (comBat), available in sva.
Gene and exon expression in non-ovarian TCGA samples. Normalized gene-and exon-level events were downloaded from the TCGA FireCloud. Exon usage was previously quantified using MapSplice (v.12_07).
Gene expression in GTEx samples. Processed and normalized gene expression and genotypes were downloaded from the database of Genotypes and Phenotypes and the GTEx Portal as described in Ardlie et al. 51 . For each tissue, the following covariates were included in all analyses: three genetic principal components; sex; platform; and 14-35 expression factors 52 as selected by the main GTEx analysis.
Clinical factors for the TCGA samples. We extracted all relevant clinical factors available for the TCGA samples for use as covariates and to evaluate expression heterogeneity (Supplementary Tables 4 and 5 ). We quantified BRCA1/2 somatic mutation carriers using MutSig 2CV (v.3.1) calls from tumor whole-exome sequencing made available by the TCGA. We quantified somatic structural variants using Birdsuite copy number variation calls from tumor and/or normal genotype array data made available by the TCGA. Tumor purity was systematically estimated across the TCGA cohorts by Aran et al. 53 .
Heritability and genetic correlation. To evaluate tumor subtype heterogeneity, we quantified the genetic correlation of gene expression between subtypes. For each panel and factor, we divided the samples into two groups either as carriers or noncarriers for dichotomous factors such as somatic BRCA1/2 mutation, or as low or high for quantitative factors such as age. Mean heritability and genetic correlation were estimated using Haseman-Elston regression 54 as implemented in Genomewide complex trait analysis (GCTA) 55 . All SNPs within 500 kb of the gene boundary were used to define the cis-locus and construct the corresponding kinship matrix. Standard errors for genetic correlation across all genes were estimated as in Falconer and Mackay 56 .
Construction and validation of gene prediction models. TWAS predictors were computed using the FUSION software (http://gusevlab.org/projects/fusion/). Briefly, for each gene or exon junction, SNPs from ± 500 kb of the feature boundary were extracted and used to estimated cis-SNP heritability 55 . The principal components of clinical features and gene expression were always included as covariates to account for trans-variation (see Supplementary Note for detailed analyses). Features that had nominally significant cis-SNP heritability (likelihood ratio test P < 0.01) were retained for model building and TWAS. We elected to use a heritability-based cutoff rather than specify a cutoff on the R 2 cross-validation because the former uses all available data; however, we report both statistics for all associations. Notably, for the 106 TWAS-significant models, 105 out of 106 has nominal cross-validation P < 0.05 and 85 out of 106 had Bonferroni-significant cross-validation P < 0.05 for the 106 TWAS models. The genotypes were used to train the TWAS predictive models using the best linear unbiased prediction, elastic net and least absolute shrinkage and selection operator algorithms.
Fivefold cross-validation was performed for each reference panel and gene and/ or splicing model. Gene expression for each fold of the data was hidden in turn; the full prediction model was then trained on the remaining expression and genetic data; then the trained model was then predicted into the held-out fold samples. This procedure was repeated across all folds to compute the overall cross-validated prediction; an adjusted R 2 (and corresponding two-tailed P) was then computed between the cross-validated prediction and the measured expression by ordinary least squares. The least absolute shrinkage and selection operator and elastic net models require a penalty parameter that is itself fit by leave-one-out crossvalidation; this was performed within each fold (that is, double cross-validation where the testing data is hidden from all parameter tuning). Across all tissues and features, the top eQTL was the best predictor only 26% of the time. Surprisingly, the best linear unbiased prediction predictor, which has the weakest penalization in favor of sparsity, was the most common best predictor (best 33% of the time), suggesting a greater degree of effect heterogeneity in these data than studies of normals where cis-expression effects are typically sparse 57 . For models trained in GTEx (v.6), TWAS expression weights were previously computed as described in Mancuso et al. 16 and downloaded from the FUSION website.
We investigated the concordance in heritability and R 2 estimates between the TCGA tumors and the corresponding healthy GTEx tissues. For each pair of TCGA-GTEx tissues, we measured the Pearson correlation (and significance) between the estimated cis-heritability across all evaluated genes. We note that the GTEx heritability estimates have greater estimation error than signal (mean cis-h 2 g estimate = 0.042, mean s.e.m. estimate = 0.045), which is expected to greatly deflate this estimate. Therefore, we additionally estimated the relationship between the two estimates using regression of GTEx estimate on TCGA estimate (Supplementary Table 11 ). We similarly evaluated the correlation between the TCGA in-sample cross-validation R 2 and the TCGA-into-GTEx prediction R 2 . Correlation of predictive models between the TCGA panels was estimated in the 1000 Genomes Project European reference samples. First, each model was predicted into the reference samples. Second, for each gene that was modeled in multiple panels and each pair of panels, the correlation between predicted values from panel 1 and panel 2 was computed. The mean correlation across all pairs of panels and shared genes is reported in Supplementary Table 12. TWAS analysis. GWAS data. GWAS data from Ovarian Cancer Association Consortium as described in Phelan et al. 7 were downloaded and aligned to hg19 HapMap 3 SNPs (excluding A/T or C/G SNPs due to strand ambiguity). These SNPs are consistently imputed with high accuracy across diverse genotyping platforms and were used to compute all TWAS weights.
TWAS tests. The FUSION software was used to perform the TWAS tests across all predictive models 17 . Models were considered 'transcriptome-wide significant' if they passed the Bonferroni correction for all genes and exon events tested.
Summary-based conditional analyses between TWAS and GWAS associations were performed using FUSION 58 . For a given significant TWAS association, the gene and/or exon expression was predicted into the 1000 Genomes Project European samples to estimate the linkage disequilibrium between the predicted model and each SNP in the locus. Each GWAS SNP was then conditioned on the predicted model using the linkage disequilibrium estimate to quantify the amount of residual association signal. Stepwise model selection was performed by including each TWAS-associated feature (from most to least significant) into the model until no feature remained conditionally significant.
Summary-based conditional analyses for individual SNPs were performed using GCTA conditional and joint analysis 58 . Colocalization analyses were performed using the COLOC software (v.3.1) 39 and the marginal eQTL/spQTL statistics for a given feature.
Conditional and colocalization analyses. First, we conditioned every GWAS association on the predicted value of each significant TWAS gene to assess how much association signal remained independent of the TWAS association (see Methods). We note that comparing GWAS and TWAS effect sizes directly poses a challenge because the associations are on different scales. GWAS effect sizes are on the allelic odds ratio scale, whereas TWAS effect sizes are on the standardized expression scale since there is no formal allele for the expression predictor. Instead, the conditional analysis serves to quantify whether the TWAS association can explain the GWAS association after accounting for correlation between the predictive model and GWAS risk SNPs. The residual GWAS signal, after conditioning, is an indicator that the TWAS association is partially tagging the causal variants, or that other independent causal variants are present at the locus (as with SNP-based conditioning).
Second, we performed a colocalization analysis using the COLOC software 39 , which evaluated the posterior probability that the genetic association to the gene and/or exon is driven by a single shared causal variant with the GWAS risk association (termed PP4 in the COLOC notation). This model does not consider colocalization between multiple causal variants, so high PP4 is a more stringent threshold to clear than the TWAS association and may miss true colocalization at loci with heterogeneous effects on expression and disease. COLOC additionally estimates the probability that the expression and GWAS are driven by two distinct causal variants (PP3); we used low PP3 as a less stringent threshold for evidence of non-independent association signal, although it may still be confounded by multiple causal variants.
Functional analyses.
CHMP4C spQTL analyses. We tested rs74758321 for association to CHMP4C junction usage in each of the TCGA cohorts (Supplementary Tables 24 and 25 ; see Nature Research Reporting Summary). To keep effect sizes as consistent as possible across the studies (and since these junctions were already shown to be highly heritable with all covariates), we did not incorporate any covariates and only performed simple rescaling of each junction count to mean 0, variance 1. We first tested each junction (in each tissue) in turn for association to the SNP by ordinary least squares regression (Supplementary  Table 24 ). We then tested the joint effect of the SNP on junction usage by reversing the regression: SNP − junction1 + junction2 + junction3 + junction4 (Supplementary Table 25 ). While the individual effect sizes from this multiple regression are difficult to interpret, the significance of each association is an indicator of which junction more strongly drives the genetic association.
For the splicing assays, iOSE11 cells were grown in NOSE-CM 59 and FUOV1 ovarian cancer cells were grown in DMEM/F12 (Thermo Fisher Scientific) supplemented with 10% FBS (Sigma-Aldrich) and l-glutamine (catalog no. 17-605E; Lonza). A minigene construct was generated to include chr8:82667209-82668009, representing CHMP4C exon 3 ± approximately 350 bp (see Supplementary Note for the primers used). iOSE11 DNA was used as a template for PCR since this cell line is heterozygous for rs74758321. PCR products were cloned into the splicing reporter vector pZW1 (ref. 60 ) to generate a pair of plasmids containing the two alleles of SNP rs74758321. The constructs were confirmed by double digestion and further verified by Sanger sequencing. Twelvewell FUOV1 ovarian cancer cells were transfected with 2 μg splicing reporter when cells reached 80% confluency. Cells were collected 24 h post-transfection and total RNA was subsequently extracted. Complementary DNA was made from 5 μg of total RNA using reverse transcription; one-twentieth of complementary DNA was used as template to amplify both the inclusion and skipping form of splicing reporter green fluorescent protein (GFP) transcript with or without CHMP4C exon 3 by PCR within 25 cycles using GFP-F and GFP-R (see Supplementary Note). PCR products were subjected to 5% PAGE and the resulting gels were imaged. Expression of each band was quantified using ImageJ software (http://imagej.nih. gov/ij/) and the inclusion rate of the target exon was calculated.
Enhancer scanning assays. We tested approximately 2 kb of tiles containing all nine (rs137960856, rs11782652, rs74544416, rs78740005, rs78724141, rs111683632, rs74758321, rs76837345, rs35094336) credible (1:100; 10/26/2015 imputation) SNPs in this locus for regulatory enhancer activity using enhancer scanning 61 in iOSE4 CMYC cells 62 . Tiles were tested in both orientations. Primers are provided in Supplementary Table 27 .
Protein stability assays. The SNP rs35094336 missense variant (p.Ala232Thr) was evaluated for CHMP4C protein stability. CHMP4C cDNA containing each allele was cloned into a pCMV6-entry vector. iOSE4 CMYC cells were stably transfected with FuGENE HD (Promega) transfection reagent and clones selected by G418 (Geneticin, 500 µg ml −1 ; Gibco). Stable clones were treated with cycloheximide (Sigma-Aldrich) for up to 48 h and protein levels were assessed. The missense variant (rs35094336) does not impact CHMP4C transcript stability.
Knockout screen data analyses. Differential gene expression analyses were performed using the OSEC, FTSEC and HGSOC datasets described earlier.
Processed CERES knockout data were downloaded 22 and data for the 13 HGSOC lines included in this study were used in our analyses.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Code, documentation for all methods and all trained TWAS models for all genes and splice variants have been made available on the TWAS/FUSION website (http://gusevlab.org/projects/fusion/). Full TWAS association statistics have been made available in an interactive database available at http://www.twas-hub.org.. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Data analysis EAGLE2, PLINK 1.9, FUSION, COLOC, GCTA, R, Bioconductor, ComBat, PEER 1.3, MutSigCV2, LD-score regression (LDSC). Custom FUSION/ COLOC software has been deposited to GitHub (http://gusevlab.org/projects/fusion/) For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Code and documentation for all methods has been made available on the TWAS/FUSION web-site (http://gusevlab.org/projects/fusion/). Trained TWAS models for all genes and splice variants and corresponding OvCa TWAS association statistics will be made available on the TWAS/FUSION web-site upon publication.
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Sample size
No sample-size calculation was performed, the largest available sample size was analyzed. Expression studies were used when a sufficient number of genes exhibited significant cis-heritability (typically N>80). The largest available GWAS study was used for prediction, which was shown to be sufficient due to the presence of replicated genome-wide significant associations.
Data exclusions Standard genotype and gene expression quality control metrics were used to exclude low-quality data points (described in manuscript). All exclusion criteria -PC outliers and samples with high genetic missingness -were pre-established based on existing QC protocol.
Replication
All gene expression models were replicated in independent cohorts and showed significant mean replication. For individual TWAS associations, 82/106 associated models were significantly correlated with expression/splicing measured in at least one independent cohort (after Bonferroni correction for 388 model-by-cohort pairs tested, with 92/106 nominally significant after Bonferroni correction for 4 cohorts tested). The remaining models are likely explained by tissue-specific activity or insufficient power in the replication cohort.
Randomization Not relevant to our study which was a retrospective association analysis.
Blinding
Investigators were blind to any identifiable information for the gene expression samples. Blinding did not apply to the GWAS/TWAS analysis because only summary-level data was used.
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Population characteristics
Women undergoing surgery for benign or malignant gynecological conditions not involving the fallopian tube or ovary from which the specimen was collected.
Recruitment
Patients were recruited from population-based studies at University College Hospital (London, UK), University of Southern
